Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable: A Systematic Review

Produced by	School of Health and Related Research (ScHARR), The University of Sheffield
Authors	Shijie Ren, Research Fellow, ScHARR, University of Sheffield, UK Hazel Squires, Senior Research Fellow, ScHARR, University of Sheffield, UK Eva Kaltenthaler, Professor of Health Technology Assessment, ScHARR, University of Sheffield, UK Emma Hock, Research Fellow, ScHARR, University of Sheffield, UK Andrew Rawdin, Research Assistant, ScHARR, University of Sheffield, UK Mark Clowes, Information Specialist, ScHARR, University of Sheffield, UK Jonathan Shamash, Senior Lecturer and Honorary Consultant Medical Oncologist, Barts Health NHS Trust, UK Constantine Alifrangis, Consultant Medical Oncologist, University College London Hospitals NHS Foundation Trust, UK
Correspondence Author	Shijie Ren, Research Fellow, ScHARR, University of Sheffield, Sheffield, UK
Date completed	8th February 2018

Source of funding: This report was commissioned by the NIHR HTA Programme as project number 17/56/02.

determined that it was most appropriate to use a piecewise analysis, by using the KM data directly until week nine and extrapolating beyond this using a Weibull distribution. The company states the choice of cut-off at week nine is because no patients have an assessment until this time, hence there is a step change at this point because of how the data were collected.

Figure 1: Cumulative hazard against time and log cumulative hazard against log time plots for pembrolizumab progression-free survival (reproduced from Figure 20 and Figure 21, page 91 CS)



The company fitted a range of parametric distributions including exponential, Weibull, log logistic, log normal, Gompertz and Generalised gamma to the data beyond 9 weeks. The Weibull distribution was chosen because it performed relatively well in terms of AIC and BIC. The CS does not report any validation by clinicians of the PFS curves. The extrapolated curves for PFS are presented in Figure 10.